31st August - 2nd September 2015, Berlin, Germany
The Type 1 Diabetes Simulator and Its Use in In Silico Clinical Trials
The development of UVA/Padova type 1 diabetes simulator will be presented in a historical perspective, highlighting the main differences between the “older generation” and this “new generation” simulator, which indeed convinced the Food and Drug Administration (FDA) to accept this tool as a substitute for preclinical trials for certain insulin treatments, including closed-loop algorithms (artificial pancreas, AP). Recent developments of the simulator will also be discussed, which now allow to simulate realistic long term in silico scenarios. The simulator has proved to be a useful tool to test robustness and safety of AP algorithms. However, its use is not limited to closed-loop control of diabetes, but can be used to answer a wider set of “what-if” kind of questions. Examples of different employments of the simulator will be provided, e.g. for assessing the usefulness of glucose prediction to generate hypoglycemic alerts or testing pharmacodynamics of new insulin molecules.
Chiara Dalla Man was born in Venice in the 1977. She received the Master Degree (cum laude) in Electrical Engineering in 2000 and the PhD in Bioengineering in 2005 both from the University of Padova. She is currently associate professor in Bioengineering at the Department of Information Engineering of the University of Padova. Her research is in the field of mathematical modeling of endocrine and metabolic systems and diabetes treatment, in collaboration with several Italian and foreign researchers. She is coauthor of more than 80 scientific articles, published in prestigious journals of the field, and member of the editorial board of Journal of Diabetes Science and Technology and Frontiers in Systems Biology.
Steffen Leonhardt, RWTH Aachen University, Germany
This talk will focus on the intrinsic principles behind closed-loop systems in physiology. We will look at the properties of positive and negative feedback loops. Starting at the general concept of homeostasis, we will move from cell physiology and organ level to systemic levels.
1987 M.S. in Computer Engineering, SUNY at Buffalo, USA
1989 Dipl.-Ing. in Electrical Engineering, TU Darmstadt, Germany
1995 Ph.D. in Control Engineering, TU Darmstadt, Germany
2001 M.D. in Medicine, J.W. Goethe University, Frankfurt, Germany
1999-2003 R&D Manager at Draeger Medical, Luebeck, Germany
Since 2003 Full professor and head of the Philips Chair for Medical Information Technology, RWTH Aachen University, Aachen, Germany
Model-based mechanical ventilation: A road trip from concept to randomized controlled trial
Mechanical ventilation is a primary support for patients with respiratory failure. However, patient condition and their individual response to treatment are heterogeneous and variable over time. Thus, general, one size fits all treatment approaches may not be suitable for many, and a more optimal, individualized approach is needed to obtain better care and outcomes. Model-based therapy offers the opportunity to individualise mechanical ventilation therapy that caters directly to patient-specific needs at any given interval, where real-time identified model parameters are used to personalize the model and optimize the resulting care based on patient-specific response. This talk focuses on the journey taking a conceptual model and model-based approach to mechanical ventilation from idea, through clinical proof of concept, and to a large randomized controlled trial – covering both the tangible and intangible success and roadblocks.
Chiew graduated from Universiti Teknologi Malaysia, with a Bachelor and a Masters of Engineering in Mechanical Engineering. He obtained his PhD at the University of Canterbury (UC), New Zealand studying model-based mechanical ventilation for patients with respiratory failure. His work spans the development of physiological models, model development, algorithm and system identification methods, and the creation of unique clinical decision metrics, to conducting clinical and animal trials. He is currently a postdoctoral fellow at Centre for Bioengineering at UC, in a range of research including leadership of a large randomized controlled trial.